In total, the research supports the existing clinical guideline from the European League Against Rheumatism, which states that to reduce cardiovascular risk in patients with PsA, it’s important to not only treat inflammatory disease, but also to screen for and treat traditional cardiovascular risk factors.2
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: A population-based cohort study. Rheumatology (Oxford). 2018 Sep 6. doi: 10.1093/rheumatology/key286. [Epub ahead of print]
- Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016 Mar;75(3):499–510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.